ABSTRACT Previous studies have shown that there is a major difference between the iron release mechanism of enterobactin, a catechol-based siderophore, and that of the hydroxamate-based siderophores such as ferrichrome. For ferric enterobactin there is an esterase that hydrolyzes the ligand during iron release. In contrast, iron is released by the hydroxamate-based siderophores and the ligands are reused in subsequent iron transport. It has been suggested that release of iron by hydroxamates occurs by reduction to the ferrous complex, a process that does not occur for ferric enterobactin. Cyclic vo tammograms of ferrichrome A and ferrioxamine B exhibit reversible one-electron waves with pH-independent formal potentials (Ef vs. the normal hydrogen electrode) -446 and -454 mV, respectively, within the range of physiological reductants. Ferric enterobactin also shows a reversible one-electron wave (at pH > 10) with Ef = -986 mV vs. the normal hydrogen electrode. From the pH dependence of this potential we estimate a reduction potential of -750 mV at pH 7. In sharp contrast to the value for the ferric hydroxamates, this value is well below the range of physiological reducing agents. The results demonstrate that the observed hydrolysis of enterobactin is a necessary prerequisite to in vivo release of iron from the siderophore via ferric ion reduction.
vo tammograms of ferrichrome A and ferrioxamine B exhibit reversible one-electron waves with pH-independent formal potentials (Ef vs. the normal hydrogen electrode) -446 and -454 mV, respectively, within the range of physiological reductants. Ferric enterobactin also shows a reversible one-electron wave (at pH > 10) with Ef = -986 mV vs. the normal hydrogen electrode. From the pH dependence of this potential we estimate a reduction potential of -750 mV at pH 7. In sharp contrast to the value for the ferric hydroxamates, this value is well below the range of physiological reducing agents. The results demonstrate that the observed hydrolysis of enterobactin is a necessary prerequisite to in vivo release of iron from the siderophore via ferric ion reduction. Clinical studies have shown that the pathogenicity of some bacteria is closely related to the availability of iron (1) , and that one defense against infection in mammals is the denial of iron to bacteria. Sequestration of serum iron by proteins such as transferrin (2, 3) reduces the ferric ion activity to levels well below those required for optimal microbial growth. Overcoming this defense mechanism by saturating serum transferrin with exogeneous iron increases dramatically the virulence of certain bacterial infections (1) . For example, intraperitoneal injection of 5 mg of iron per kg of body weight decreases the number of Escherichia coli cells necessary to kill rats by five orders of magnitude (4) . Thus the means by which microorganisms acquire iron has significant clinical ramifications.
Although the importance of iron to living systems can scarcely be overemphasized, the means by which bacteria acquire this vital element received little attention prior to the discovery by Neilands of ferrichrome, an iron-transporting chelate (siderophore), in 1952 (5). Aerobic microorganisms have a particularly severe problem acquiring iron, because in oxidizing environments iron is available only as ferric ion, for which a saturated solution is about 10(18 molar at physiological
-10-39) (6) . This problem has been circumvented in many prokaryotes by the evolution of ferrichrome and other siderophores, ligands that bind ferric ion with extreme avidity and selectivity, thereby solubilizing it for metabolic incorporation (7).
The two most common siderophore classes contain hydrox- (7) .
Despite the similarity in function and regulation, there is a basic difference in the mechanism of intracellular iron release from the complexes of the hydroxamates and enterobactin. The hydroxamate chelates are reused by the cell-after intracellular iron release the iron-free ligand is once again secreted into the medium. Intracellular release of iron from the hydroxamate chelates probably occurs by reduction to the ferrous state, converting the tightly bound ferric complex to the loosely bound ferrous complex,* from which the iron can be easily extracted and the intact ligand can be recycled (11) . Thus one siderophore molecule can shuttle more than one iron ion into the organism. By contrast, the cyclic triester linkages of ferric enterobactin are cleaved by an esterase specific for the ferric complex (12, 13) . Esterase-deficient mutants are colored pink due to intracellular ferri-enterobactin (in contrast to the white cells of the parent strain) but grow poorly under iron stress, establishing that esterase activity is vital to enterobactin-mediated transport. Furthermore, the bacteria are unable to use the cleavage product, 2,3-dihydroxybenzoylserine, as a substrate for enterobactin synthesis, which occurs instead via condensation of 2,3-dihydroxybenzoic acid and serine. (12) . Thus each molecule of enterobactin yields one iron atom to the cell and then is destroyed. The enormous waste of metabolic energy
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact.
- 
RESULTS
Cyclic voltammograms of ferrichrome A and ferrioxamine B are shown in Fig. 4 (8) . A separation between extrema in the cyclic voltammogram of 59/n mV is expected for a reversible n-electron process at 25°. The observed separation of 60 mV, its scan rate independence, and the ratio of peak cathodic to anodic currents of nearly unity are all consistent with electrochemical reversibility for both ferrichrome A and ferrioxamine B. The half-wave potentials for reversible couples can be equated to the thermodynamic midpoint potential within an excellent approximation. The midpoint potentials of the two hydroxamates are essentially independent of pH over the region 8-12, as expected for a redox process involving no protons. Ferric enterobactin, like ferrichrome A and ferrioxamine B, yields a reversible one-electron wave, as evidenced by the scan rate-independent 60-mV separation between extrema and the peak current ratio. In sharp contrast to the hydroxamate complexes, however, is the much lower midpoint potential for this process, -1230 mV vs. SCE, or -986 mV vs. NHE (Fig. 4 bottom) .
DISCUSSION
The cyclic voltammetry data on these three biological chelates demonstrate that all are reversibly reduced electrochemically. We are unable to account for previous reports (12) that ferric enterobactin is unreducible down to -1.8 V vs. SCE. In our experiments, reversible loss of the ligand-to-metal charge transfer band characteristic of the ferric complex upon exhaustive reduction proves that reduction of ferric enterobactin is occurring.
The salient feature of the cyclic voltammetry results is the striking difference in reduction potential between the hydroxamates and ferric enterobactin chelates. and ferrioxamine B have reduction potentials within the physiological range, but that of ferric enterobactin is well below that of any known physiological reductant. Below pH 10.5 the cyclic voltammogram of ferric enterobactin exhibits peakto-peak separations exceeding 60 mV, typical of an irreversible process. Similar behavior is found for ferric tris (catecholate), for which raising the total catechol concentration extends the pH region over which reversible waves are observed.
Although the ferric enterobactin cyclic voltammograms are not strictly reversible below pH 10, the Fe(III)-enterobactin reduction potential can be approximated as the average of the peak potentials for quasireversible waves (AE = 75 mV). The observed increase in reduction potential with decrease in pH ( These observations are consistent with intracellular iron release occurring via reduction to Fe(II), although they do not prove that this mechanism is operative in vivo. The hydroxamic acid chelates are thermodynamically readily reducible by physiologically available reductants such as pyridine nucleotides, yielding the weakly bound ferrous complex (log K 9)* from which the iron can be easily removed and the ligand recycled. In contrast, the inordinately low reduction potential of ferric enterobactin would necessitate hydrolysis of the chelate ester linkages, with concomitant increase in ferric reduction potential, as a prerequisite to physiological reduction and removal of the ferric ion.
Despite the considerable expenditure of metabolic energy to synthesize enterobactin for just one use, a large competitive advantage is conferred on the bacteria by enterobactin-mediated iron transport. The immense stability constant of ferric enterobactin (ent) [Fe(III) + ent6-Fe(ent)3-; log K = 52]t allows bacteria synthesizing it to acquire iron present at extremely low concentrations-probably much lower than those that will sustain microorganisms utilizing chelates with less affinity for ferric ion. Thus bacteria employing enterobactin for iron acquisition tend to deny iron to microorganisms using other ligands. In order to free the iron for their own use, the bacteria must destroy the enterobactin, which serves to make iron uptake irreversible. The relatively labile ester linkages of enterobactin may be designed specifically to facilitate this destruction, in comparison with the more robust amide linkages, for example. In this light it is interesting that the only known polycatechol chelate without labile linkages [a spermidine conjugate with 2,3-dihydroxybenzoic acid (14) ] has only two catechols. If our hypothesis is correct, the ferric complex of this ligand should have a redox potential near those of the hydroxamic acid chelates.
CONCLUSIONS
The cyclic voltammetry results reported here show that representative microbial hydroxamate iron transport chelates (siderophores) are reduced at potentials near those of physiological reductants such as NAD(P)H. Thus iron removal from these complexes can be effected simply by iron reduction to the weakly bound ferrous state, allowing reuse of the ligand. The extremely low redox potential of ferric enterobactin precludes this mechanism and supports the suggestion that hydrolytic depolymerization of the chelate is a prerequisite for physiological reduction and removal of the iron.
